Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patients
Background: Iron deficiency is an important co-morbidity in heart failure patients. IV iron may improve quality of life and reduce heart failure hospitalizations, but the results of the clinical trials are varied. Objective: The purpose of this meta-analysis is to assess not only the effect of IV ir...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | American Heart Journal Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602222001215 |
| _version_ | 1811239361180598272 |
|---|---|
| author | Phyo Thazin Myint Phoo Pwint Nandar Aye M. Thet Gabriela Orasanu |
| author_facet | Phyo Thazin Myint Phoo Pwint Nandar Aye M. Thet Gabriela Orasanu |
| author_sort | Phyo Thazin Myint |
| collection | DOAJ |
| description | Background: Iron deficiency is an important co-morbidity in heart failure patients. IV iron may improve quality of life and reduce heart failure hospitalizations, but the results of the clinical trials are varied. Objective: The purpose of this meta-analysis is to assess not only the effect of IV iron in iron-deficient heart failure patients but also the quality of evidence. Methods: PubMed and Cochrane databases were searched from inception to Oct 2021. Randomized clinical trials in iron-deficient, heart failure patients assessing the effect of IV iron versus placebo and with at least 12 weeks of follow-up were included. The outcomes were pooled and analyzed using a random-effect model. The quality of evidence was assessed using the GRADE approach. Results: Seven studies were included in our meta-analysis. IV iron was associated with a 13.8 % decreased risk of HF hospitalizations (OR 0.59; 0.35–0.98, p = 0.040, GRADE = Low). All-cause mortality and CV mortality were not different between IV iron and placebo. But a composite outcome of HF hospitalizations or CV mortality was 17.5 % lower with IV iron (OR 0.51;0.31–0.84, p = 0.008, GRADE = Moderate). Conclusions: Among heart failure patients with iron deficiency, IV iron is associated with lower HF hospitalizations. It is a relatively inexpensive regimen that can potentially improve quality of life and decrease healthcare expenditure. |
| first_indexed | 2024-04-12T12:58:29Z |
| format | Article |
| id | doaj.art-b58402c0113142548dd9b28516054e09 |
| institution | Directory Open Access Journal |
| issn | 2666-6022 |
| language | English |
| last_indexed | 2024-04-12T12:58:29Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Heart Journal Plus |
| spelling | doaj.art-b58402c0113142548dd9b28516054e092022-12-22T03:32:15ZengElsevierAmerican Heart Journal Plus2666-60222022-10-0122100204Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patientsPhyo Thazin Myint0Phoo Pwint Nandar1Aye M. Thet2Gabriela Orasanu3Department of Hospital Medicine, Baystate Medical Center, Springfield, MA, USA; Corresponding author at: 1703 Canyon Ridge Drive, Broad Brook, CT 06016, USA.Department of Cardiology, Summa Health System, Akron, OH, USADepartment of Hematology & Oncology, Ascension Macomb-Oakland Hospital, Warren, MI, USADepartment of Cardiology, Summa Health System, Akron, OH, USABackground: Iron deficiency is an important co-morbidity in heart failure patients. IV iron may improve quality of life and reduce heart failure hospitalizations, but the results of the clinical trials are varied. Objective: The purpose of this meta-analysis is to assess not only the effect of IV iron in iron-deficient heart failure patients but also the quality of evidence. Methods: PubMed and Cochrane databases were searched from inception to Oct 2021. Randomized clinical trials in iron-deficient, heart failure patients assessing the effect of IV iron versus placebo and with at least 12 weeks of follow-up were included. The outcomes were pooled and analyzed using a random-effect model. The quality of evidence was assessed using the GRADE approach. Results: Seven studies were included in our meta-analysis. IV iron was associated with a 13.8 % decreased risk of HF hospitalizations (OR 0.59; 0.35–0.98, p = 0.040, GRADE = Low). All-cause mortality and CV mortality were not different between IV iron and placebo. But a composite outcome of HF hospitalizations or CV mortality was 17.5 % lower with IV iron (OR 0.51;0.31–0.84, p = 0.008, GRADE = Moderate). Conclusions: Among heart failure patients with iron deficiency, IV iron is associated with lower HF hospitalizations. It is a relatively inexpensive regimen that can potentially improve quality of life and decrease healthcare expenditure.http://www.sciencedirect.com/science/article/pii/S2666602222001215Intravenous IronHeart failureIron deficiencyMeta-analysis |
| spellingShingle | Phyo Thazin Myint Phoo Pwint Nandar Aye M. Thet Gabriela Orasanu Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patients American Heart Journal Plus Intravenous Iron Heart failure Iron deficiency Meta-analysis |
| title | Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patients |
| title_full | Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patients |
| title_fullStr | Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patients |
| title_full_unstemmed | Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patients |
| title_short | Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patients |
| title_sort | cost effective heart failure management meta analysis of iv iron therapy in iron deficient heart failure patients |
| topic | Intravenous Iron Heart failure Iron deficiency Meta-analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2666602222001215 |
| work_keys_str_mv | AT phyothazinmyint costeffectiveheartfailuremanagementmetaanalysisofivirontherapyinirondeficientheartfailurepatients AT phoopwintnandar costeffectiveheartfailuremanagementmetaanalysisofivirontherapyinirondeficientheartfailurepatients AT ayemthet costeffectiveheartfailuremanagementmetaanalysisofivirontherapyinirondeficientheartfailurepatients AT gabrielaorasanu costeffectiveheartfailuremanagementmetaanalysisofivirontherapyinirondeficientheartfailurepatients |